AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

ClinicalTrials.gov ID: NCT07454642

Public ClinicalTrials.gov record NCT07454642. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6103, a Novel FAP-activated Exatecan Administered Intravenously in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.

Study identification

NCT ID: NCT07454642
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Avacta Life Sciences Ltd; Industry
Enrollment: 174 participants

Conditions and interventions

Conditions

Interventions

AVA6103 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2026 (Actual)
Primary completion: Jan 2029 (Estimated)
Completion: Jun 2030 (Estimated)
Last update posted: Oct 5, 2026

2026 – 2030

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Honor Health Research Institute	Scottsdale	Arizona	85258	Recruiting
Florida Cancer Specialists and Research Institute	Sarasota	Florida	34232	Recruiting
The University of Chicago	Chicago	Illinois	60637	Recruiting
START Midwest	Grand Rapids	Michigan	49546	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
NEXT Oncology	Irving	Texas	75039	Recruiting
NEXT Oncology Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07454642, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 5, 2026 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07454642 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →